IDEAYA Biosciences (IDYA) stock is in focus after the company enrolled the first patient in a Phase 1 trial that combines IDE892 and IDE397 for MTAP-deleted solid tumors, including pancreatic and non-small cell lung cancers.

At a share price of $30.57, IDEAYA Biosciences has seen strong short term momentum, with a 7 day share price return of 10.76% and a 30 day share price return of 7.94%. However, the 90 day share price return declined 6.23%, while the 1 year total shareholder return of 39.84% contrasts with more muted year to date share price performance. This suggests sentiment has cooled after earlier gains, despite recent trial progress, the Roche collaboration and the June follow on equity offering.

If IDEAYA Biosciences' latest trial milestone has you thinking about other precision oncology opportunities, it could be a good time to review 40 healthcare AI stocks.

With IDEAYA Biosciences trading at $30.57 and sitting at a sizeable discount to the average analyst price target and some intrinsic value estimates, the key question is whether this signals a genuine opportunity or if the market is already pricing in future growth.

Preferred Price-to-Sales Multiple of 11.9x: Is It Justified?

On the numbers alone, IDEAYA Biosciences looks expensive relative to some benchmarks, yet cheaper than others. This makes its $30.57 share price worth a closer look against the 11.9x P/S tag.

The preferred metric here is the price-to-sales ratio, which compares IDEAYA Biosciences' market value to its $225.27 million of revenue. For a company that is still reporting a loss of $140.06 million and is forecast to remain unprofitable over the next 3 years, revenue-based metrics are often the primary way investors compare valuations while the business is still in the investment and clinical development phase.

There is a split verdict on value. On one hand, IDEAYA Biosciences is described as trading at a substantial 81.5% discount to an internal estimate of fair value, and the SWS DCF model suggests the stock at $30.57 is below an estimated future cash flow value of $165.44. On the other hand, based on that 11.9x P/S, the stock is considered expensive versus an estimated fair price-to-sales ratio of 2.7x and also expensive compared to the wider US Biotechs industry average of 10.5x. This implies the current multiple is above where the market could potentially move if sentiment or growth expectations reset.

Result: Preferred multiple of price-to-sales ratio of 11.9x (OVERVALUED)

However, IDEAYA Biosciences still faces clear risks, including its current loss of $140.06 million, as well as the uncertainty around future clinical trial outcomes and partnerships.

Another View: What The SWS DCF Model Says About IDEAYA Biosciences

While the current 11.9x P/S ratio suggests IDEAYA Biosciences stock screens as expensive against some benchmarks, the SWS DCF model points in the opposite direction, with a fair value estimate of $165.44 compared with the current $30.57 share price. That gap frames a very different question about risk and potential reward.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out IDEAYA Biosciences for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment on IDEAYA Biosciences split between clear risks and potentially attractive rewards, it makes sense to move quickly, review the underlying data, and pressure test your own thesis using the 2 key rewards and 1 important warning sign

Looking For More Investment Ideas Beyond IDEAYA Biosciences?

If you are serious about building a stronger portfolio than IDEAYA Biosciences alone can offer, now is the moment to scan for other high conviction opportunities.

• Spot potential mispricings early by reviewing the 44 high quality undervalued stocks that pair quality fundamentals with discounted valuations.
• Strengthen your income stream by checking out the 9 dividend fortresses built around companies with yields that stand out.
• Get ahead of the crowd by scanning the screener containing 20 high quality undiscovered gems before other investors start paying attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.